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Abstract
Background: Delayed elimination of methotrexate was previously reported in 2 patients receiving concomitant levetiracetam.
Objective: To explore the potential interaction between methotrexate and levetiracetam in patients receiving high-dose
methotrexate. Methods: This retrospective study reviewed the records of 81 adults receiving 280 cycles of methotrexate to
determine the effects of levetiracetam on methotrexate elimination. Institutional review board approval was obtained. Results:
Levetiracetam was administered in 33 (12%) cycles of methotrexate. Patients receiving levetiracetam had significantly lower
24-hour methotrexate concentrations compared with those not receiving levetiracetam (2.91 vs 7.37 µmol/L, P = 0.005).
Despite this difference, concentrations at 48 and 72 hours were similar between groups. Times to nontoxic methotrexate
concentration (<0.1 µmol/L) were the same regardless of the presence of levetiracetam. The frequency of delayed elimination
at 24, 48, and 72 hours was similar in both groups as was the frequency of delayed elimination at any time point. Cox
regression demonstrated that levetiracetam was not a significant predictor of time to nontoxic methotrexate concentration
(P = 0.796; HR = 1.058; 95% CI = 0.692-1.617), and logistic regression demonstrated that levetiracetam was not a significant
predictor of delayed elimination at any time point. Levetiracetam use was similar between groups when comparing patients
experiencing delayed elimination at any time point with those without delayed elimination (13% vs 10%, respectively, P =
0.527). Conclusion: This study does not support the previous reports of a significant interaction between levetiracetam
and methotrexate. A clinically significant interaction is unlikely in those without additional risk factors for delayed elimination.
Keywords
methotrexate, drug interactions, pharmacokinetics, seizures, drug monitoring

Introduction
High-dose methotrexate protocols are utilized in the treatment of various cancers. Methotrexate is an antimetabolite
that interferes with DNA synthesis by inhibiting dihydrofolate reductase, preventing the synthesis of purine nucleotides
and thymidylate, and causing the subsequent death of cancer
cells.1 It was the first agent to provide a cure for cancer as
monotherapy, and it has continued to remain a cornerstone
of various anticancer regimens throughout the years.2
Unfortunately, methotrexate is also well known for its many
drug interactions, which require careful management during
therapy. The majority of methotrexate undergoes renal elimination and can be influenced by renal function, urinary
pH, and coadministration of medication competing for elimination.3,4 Methotrexate also undergoes hepatic metabolism
via cytochrome P-450 isoenzymes. Because of these issues
with methotrexate pharmacokinetics, serum methotrexate

concentrations are routinely monitored at 24, 48, and 72
hours after the start of the methotrexate infusion with standard goal concentrations being ≤10 to 20 µmol/L at 24 hours
(depending on duration of infusion), ≤1 µmol/L at 48 hours,
and ≤0.1 µmol/L at 72 hours.3,5
Many antiepileptic agents utilize the same metabolic
pathways as methotrexate, resulting in increased or decreased
serum drug concentrations of one or the other.6 These interactions could be detrimental to patient outcomes if not properly managed because they could result in increased toxicity,
1
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loss of seizure control, or decreased efficacy of the oncological agent. Of particular concern is that interactions resulting
in delayed methotrexate elimination may result in substantial increases in potentially life-threatening toxicity, including myelosuppression, mucositis, hepatotoxicity, and
nephrotoxicity. Although it is best practice to avoid drugdrug interactions, scenarios arise in which this is not always
feasible.
Levetiracetam has become one of the preferred antiepileptic agents used in patients with malignancies because
of its limited potential for drug interactions.6 Historically,
no drug-drug interaction between methotrexate and levetiracetam had been identified; however, 2 cases in which
levetiracetam appears to cause a delay in the elimination
of methotrexate have recently been published.7,8 Given the
seriousness of any drug interaction with methotrexate, a
retrospective study was completed to explore the possibility of a drug-drug interaction between methotrexate and
levetiracetam.

Methods
Study Design
A retrospective chart review was performed on qualifying
patients admitted between January 1, 2008, and August 1,
2014, to a community teaching hospital. Adult patients at
least 18 years old with an oncological diagnosis, who
received at least 1 treatment of high-dose methotrexate
(≥1000 mg/m2 intravenously [IV] over 3-4 hours or ≥800
mg/m2 IV over 22-24 hours) were included in the study.
Patients receiving multiple cycles of high dose methotrexate were included in the study multiple times (once for each
cycle). Patients were excluded from the study if they were
pregnant or if methotrexate serum concentrations were not
monitored. Potential participants were identified via the
hospital’s electronic medical record system. The study
design was reviewed and approved by the local institutional
review board.

Data Collection
Electronic medical records were followed until plasma concentrations of methotrexate were nontoxic (≤0.1 µmol/L).
Baseline characteristics, including demographic data, were
gathered for all patients. Additionally, factors related to
methotrexate administration and elimination, such as leucovorin use, presence of pleural effusion or ascites, use of
urinary alkalinization, urine pH, alanine transaminase
(ALT), aspartate transaminase (AST), baseline serum creatinine, and methotrexate dose and infusion time were collected. The Cockroft-Gault formula was used to estimate
creatinine clearance.9 The coadministration of the following
medications with the potential to interact with methotrexate

elimination was noted: dantrolene, cephalosporins, aspirin,
penicillins, sulfamethoxazole/trimethoprim, nonsteroidal
anti-inflammatory drugs, and probenecid. Methotrexate
concentrations were routinely monitored at 24, 48, and 72
hours per hospital protocol. Patients with concentrations
>0.1 µmol/L at 72 hours were routinely monitored daily,
thereafter. The dose and schedule of levetiracetam were
also noted.

End Points
The primary end point of the study was to determine
whether coadministration of levetiracetam with methotrexate resulted in more instances of delayed elimination
of methotrexate at any time point after administration
when compared with patients who did not receive levetiracetam. Delayed elimination was defined as plasma
methotrexate concentrations of >10 µmol/L at 24 hours if
receiving bolus infusion methotrexate (ie, over 3-4 hours)
or >20 µmol/L at 24 hours if receiving infusional methotrexate (ie, over 22-24 hours), >1 µmol/L at 48 hours, and
>0.1 µmol/L at 72 hours. Secondary end points included a
comparison of the proportion with delayed elimination at
24, 48, and 72 hours; time to nontoxic methotrexate concentrations (<0.1 µmol/L); and a comparison of levetiracetam use among those with and without delayed
elimination.

Statistical Analysis
Patient baseline characteristics were compared using χ2,
Fisher’s exact, and Mann-Whitney U tests as appropriate.
Analyses were completed on the entire study population as
well as a subgroup of those receiving bolus methotrexate
dosing to account for the differing 24-hour goals in those
receiving bolus and infusional methotrexate (≤10 and ≤20
µmol/L, respectively) and the fact that all patients receiving
levetiracetam received bolus infusions. Binary logistic
regression was utilized to evaluate the primary end point:
delayed elimination at any time point. The following variables were included: baseline creatinine clearance, number
of interacting medications, baseline AST, baseline ALT, and
use of levetiracetam. Cox regression was utilized to evaluate if levetiracetam was a significant predictor of time to
nontoxic methotrexate concentrations, with the following
variables included: baseline creatinine clearance, number of
interacting medications, baseline AST, baseline ALT, and
use of levetiracetam. Delayed elimination at 24, 48, and 72
hours was compared via the Mann-Whitney U test, and
levetiracetam use among those with and without delayed
elimination was compared using the χ2 test. Data were analyzed using IBM SPSS Statistics for Windows, version 22
(IBM Corp, Armonk, NY). A P value <0.05 was considered
to be statistically significant.
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Table 1. Baseline Characteristics.
Entire Population
(n = 280)
No LEV
(n = 247)
Baseline characteristic
Male, n (%)
175 (71)
Age, years, median (IQR)
52 (24)
1.99 (0.36)
Body surface area, m2, median (IQR)
Baseline creatinine clearance, mL/min, median (IQR)
91 (55)
Baseline AST, U/L, median (IQR)
20 (15)
Baseline ALT, U/L, median (IQR)
39 (21)
Diagnosis, n (%)
ALL
30 (12)
Burkitt’s lymphoma
41 (17)
CNS lymphoma
93 (38)
Leptomeningeal carcinomatosis
1 (<1)
Mantle cell lymphoma
16 (7)
NHL
33 (13)
NHL (testicular)
3 (1)
Osteosarcoma
17 (7)
T-cell lymphoma
13 (5)
Total methotrexate dose, mg, median (IQR)
6000 (5100)
Long methotrexate infusion time (22-24 hours), n (%)
114 (46)
Number of interacting medications, n (%)
0
199 (81)
1
37 (15)
2
11 (4)
Pleural effusion, n (%)
1 (<1)
Ascites, n (%)
1 (<1)

Population Receiving Bolus Infusions
(n = 166)

LEV (n = 33)
14 (42)
57 (21)
1.92 (0.57)
89 (57)
23 (8)
53 (22)

P
0.001
0.003
0.267
0.301
0.382
0.003

2 (6)
3 (9)

27 (82)
5 (15)
1 (3)
0 (0)
0 (0)

LEV
(n = 33)

P

83 (62)
54 (23)
2.0 (0.37)
82 (44)
19 (16)
39 (36)

14 (42)
57 (21)
1.92 (0.57)
89 (57)
23 (8)
53 (22)

0.037
0.004
0.352
0.711
0.247
0.034

2 (2)
2 (2)
85 (64)
1 (<1)
1 (<1)
23 (17)

28 (85)

6800 (1895)
0 (0)

No LEV
(n = 133)

0.012
<0.001
0.931

1.0
1.0

28 (85)

2 (6)

17 (13)
2 (2)
7000 (1700)

3 (9)
6800 (1895)

0.362

108 (81)
19 (14)
6 (5)
0 (0)
1 (<1)

27 (82)
5 (15)
1 (3)
0 (0)
0 (0)

1
1

Abbreviations: ALL, acute lymphoblastic leukemia; ALT, alanine transaminase; AST, aspartate transaminase; CNS, central nervous system; IQR,
interquartile range; LEV, levetiracetam; NHL, non-Hodgkin’s lymphoma.

Results
Patient Characteristics
A total of 81 patients were identified and included, which
represented 280 unique cycles of high-dose methotrexate.
Levetiracetam was administered concurrently in 13 patients
receiving a total of 33 cycles. Based on the number of
patients, the study had 90% power to detect a 20% increase
in the incidence of delayed elimination at any time point
after administration. Baseline characteristics were well balanced among the 2 groups, except for more cycles occurring in slightly younger males in the group not receiving
levetiracetam (Table 1). Additional differences in baseline
characteristics of the entire population included baseline
ALT and differences in methotrexate dosing because those
receiving levetiracetam were likely to receive higher doses
via a bolus infusion, which is consistent with the fact that
the majority of the patients in the levetiracetam group had
central nervous system malignancies. When the subgroup
of cycles that utilized bolus infusions (≤4 hours in duration)

was analyzed, it represented 59% of the methotrexate cycles
(n = 166), and the baseline characteristics largely mirrored
the entire population (Table 1). Disparities in methotrexate
dosing between groups that were present in the entire population were not present in the subgroup receiving bolus
infusions. Levetiracetam dosing ranged from 500 mg daily
to 1500 mg twice daily, with the majority receiving 500 mg
twice daily, and all patients were either receiving levetiracetam prior to admission or stabilized on it prior to the start of
methotrexate.

Supportive Management of Methotrexate
Therapy
No differences were observed in the supportive care patients
received in either the entire population or those receiving
bolus infusions only. All patients received urinary alkalinization and leucovorin rescue. Urine pH was 7 or higher in at
least 96% of patients at 24, 48, and 72 hours after the start
of the methotrexate infusion, and there were no differences
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Table 2. Methotrexate Management and Monitoring.
Creatinine Clearance, mg/dL; median
(IQR)
Entire population
Time after start of MTX infusion (hours)
No LEV
Number with result available
Result
LEV
Number with result available
Result
P value
Bolus infusion subgroup
No LEV
Number with result available
Result
LEV
Number with result available
Result
P value

Urine pH ≥7, n (Percentage of Those With
Result Available)

24
184
86 (57)
30
84 (49)
0.568

48
191
86 (63)
30
85 (47)
0.278

72
150
81 (58)
22
66 (54)
0.232

24
223
213 (96)
33
33 (100)
0.369

48
236
231 (98)
33
32 (97)
0.548

72
177
170 (96)
24
24 (100)
1.0

110
82 (43)
30
84 (49)
0.571

104
82 (42)
30
85 (47)
0.909

83
78 (61)
22
66 (54)
0.389

129
125 (97)
33
33 (100)
0.583

127
127 (100)
33
32 (97)
0.206

102
102 (100)
24
24 (100)
1.0

Abbreviations: IQR, interquartile range; LEV, levetiracetam; MTX, methotrexate.

between groups in the proportion of patients with a pH ≥7
(Table 2). Renal function, as represented by creatinine
clearance, was also similar between groups at 24, 48, and 72
hours after the start of the methotrexate infusion. These
characteristics were similar in the population receiving
bolus infusions (Table 2).

Methotrexate Concentrations and Elimination
In the entire population, methotrexate concentrations were
similar at 48 and 72 hours after the start of methotrexate;
however, median concentrations were higher at 24 hours in
those not receiving levetiracetam (7.37 vs 2.91 µmol/L, P =
0.005; Table 3). Despite this difference in concentrations at
24 hours, there was no difference in the proportion of
patients with delayed elimination at 24, 48, or 72 hours after
the start of methotrexate, nor was there a difference in the
proportion of patients experiencing delayed elimination at
any time point. Logistic regression demonstrated that the
only significant predictor of delayed elimination at any time
point was baseline creatinine clearance (P = 0.012), whereas
all other parameters were nonsignificant, including receipt
of levetiracetam (P = 0.887). Median time to a nontoxic
methotrexate concentration (methotrexate concentration <
0.1 µmol/L) was also similar among groups (72 hours in
those receiving no levetiracetam vs 78 hours in those receiving levetiracetam, P = 0.229). When data were analyzed
utilizing Cox regression, receipt of levetiracetam was not a
significant predictor of time to nontoxic methotrexate concentrations (P = 0.796; HR = 1.058; 95% CI = 0.692-1.617;
Figure 1). The only significant predictor was baseline creatinine clearance (P = 0.017; HR = 1.004; 95%
CI = 1.001-1.008).
In the population receiving only bolus infusions, the difference in the median 24-hour methotrexate concentration

observed in the entire population was not present (4.06
µmol/L in those receiving no levetiracetam vs 2.91 in those
receiving levetiracetam; P = 0.864; Table 3). All other
parameters were similar to the entire population, including
the proportion of those with delayed elimination and the
median time to nontoxic methotrexate concentrations (Table
3). Logistic regression was also similar, in that baseline creatinine clearance was the only significant predictor of
delayed elimination at any time (P < 0.001). Likewise, Cox
regression in this population demonstrated that levetiracetam was not a significant predictor of time to nontoxic
methotrexate concentration (P = 0.342; HR = 1.258; 95%
CI = 0.784-2.019). Similar to the entire population, baseline
creatinine clearance was the only significant predictor of
time to nontoxic concentration in this subgroup (P = 0.014;
HR = 1.008; 95% CI = 1.002-1.014).

Analysis of Levetiracetam Use in Those With/
Without Delayed Methotrexate Elimination
In addition to comparing those receiving levetiracetam with
those not receiving the medication, data were also compared based on the presence or absence of delayed methotrexate elimination (Table 4). Patients experiencing delayed
methotrexate elimination tended to be older (49 vs 56 years
old in the entire population, P = 0.003; 49 vs 57 years old in
those receiving bolus infusions, P = 0.005). In those receiving bolus infusions, patients experiencing delayed elimination had a lower baseline creatinine clearance (101 vs 76
mL/min, P < 0.001) and a lower body surface area (2.03 vs
1.98 m2, P = 0.012). Moreover, in the entire population,
patients experiencing delayed elimination received higher
doses of methotrexate (3500 vs 3000 mg/m2, P = 0.002).
The number of patients receiving levetiracetam in the group
experiencing delayed elimination was similar to that in the
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Table 3. Methotrexate Concentrations and Elimination.a
Methotrexate Concentration, µmol/L,
Median (IQR)
Time after start of MTX infusion
(hours)
Entire population
No LEV
Number with
results available
Result
LEV
Number with
results available
Result
P value
Bolus infusion subgroup
No LEV
Number with
results available
Result
LEV
Number with
results available
Result
P value

24

48

72

219

247

228

7.37 (15.78) 0.24 (0.57)
33
33

0.07 (0.16)
31

2.91 (7.71)
0.005

0.33 (0.66)
0.771

0.11 (0.19)
0.896

132

133

126

4.06 (6.57)
33

0.24 (0.52)
33

0.07 (0.15)
31

2.91 (7.71)
0.864

0.33 (0.60)
0.502

0.11 (0.19)
0.695

Delayed Elimination, n (%)
24

48

Delayed Elimination at Time to Methotrexate Concentration
Any Time, n (%)
<0.1 µmol/L, hours, median (IQR)

72

56 (23) 34 (14) 145 (59)

4 (12)
0.095

174 (70)

72 (29)

6 (18)
0.496

23 (70)
0.344

25 (76)
0.527

78 (48)
0.229

25 (19) 18 (14)

80 (60)

91 (68)

72 (24)

23 (70)
0.411

25 (76)
0.411

78 (48)
0.123

4 (12)
0.357

6 (18)
0.580

Abbreviations: IQR, interquartile range; LEV, levetiracetam; MTX, methotrexate.
a
Percentages for delayed elimination and delayed elimination at any time are based on the total population included in each group.

Figure 1. One minus cumulative event rate (time to nontoxic
methotrexate concentration).

group not experiencing delayed elimination, as was the
number of other interacting medications received by
patients (Table 4).

Discussion
Methotrexate is an essential component in several cancer
regimens, including in those patients with primary central
nervous system lymphoma, who often require treatment for
seizures. Levetiracetam for the treatment and prevention of
seizures in those receiving chemotherapy has been utilized

largely because of the relative lack of drug interactions compared with other antiepileptic medications, such as phenytoin. However, 2 case reports have called into question the
safety of this combination. In the first case report, a 15-yearold male patient with B-cell acute lymphoblastic leukemia
experienced methotrexate toxicity when it was administered
at a dose of 5 g/m2 concomitantly with levetiracetam.7 The
patient had no risk factors for methotrexate toxicity; however, during his third infusion of high-dose methotrexate,
after starting oral levetiracetam 7.5 mg/kg twice daily, he
experienced elevated methotrexate concentrations, hypertension, renal failure, and uncontrollable vomiting. The
patient required treatment with carboxypeptidase G2 for
the elevated methotrexate concentrations and renal failure.
The second case reported in the literature included a 46-yearold male patient receiving methotrexate 12 g/m2 for relapsed
osteosarcoma.8 Prior to his second cycle of methotrexate, he
was started on levetiracetam to control seizures caused by
brain metastases. Although methotrexate elimination was
slightly delayed during cycle 1 (time to methotrexate concentration <0.1 µmol/L = 90 hours), it was delayed even further during cycles 2 to 4, during which levetiracetam was
concomitantly administered (time to methotrexate concentration <0.1 µmol/L = 106-144 hours). During cycle 5, lorazepam was substituted for levetiracetam, and methotrexate
elimination was similar to that in cycle 1 (time to methotrexate concentration <0.1 µmol/L = 95 hours).
The mechanism by which levetiracetam is thought to
delay methotrexate elimination is not confirmed, but it may
be related to the significant renal clearance of both medications. Methotrexate is cleared via glomerular filtration and
active tubular secretion, as is the metabolite of levetiracetam (ucbL057).8 The excretion of both methotrexate and
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Table 4. Comparison of Characteristics in Patients With Delayed Versus No Delayed Methotrexate Elimination.
Entire Population
(n = 280)

Baseline Characteristic
Male, n (%)
Age, years, median (IQR)
Body surface area, m2, median (IQR)
Baseline creatinine clearance, mL/min, median (IQR)
Baseline AST, U/L, median (IQR)
Baseline ALT, U/L, median (IQR)
Diagnosis
ALL
Burkitt’s lymphoma
CNS lymphoma
Leptomeningeal carcinomatosis
Mantle cell lymphoma
NHL
NHL (testicular)
Osteosarcoma
T-cell lymphoma
Total methotrexate dose, mg, median (IQR)
Long methotrexate infusion time (22-24 hours), n
(%)
Number of interacting medications, n (%)
0
1
2
Pleural effusion, n (%)
Ascites, n (%)
Receiving levetiracetam, n (%)

No Delayed
Elimination
(n = 81)

Delayed
Elimination
(n = 199)

57 (70)
49 (26)
1.99 (0.36)
97 (52)
19 (14)
38 (24)

132 (66)
56 (23)
1.92 (0.57)
85 (53)
21 (13)
40 (26)

12 (15)
11 (14)
25 (31)
1 (1)
3 (4)
17 (21)
1 (1)
6 (7)
5 (6)
5900 (5500)
31 (38)

18 (9)
30 (15)
96 (48)
13 (7)
18 (9)
2 (1)
14 (7)
8 (4)
6300 (5200)
83 (41)

70 (86)
8 (10)
3 (4)
0 (0)
0 (0)
8 (10)

156 (78)
34 (17)
9 (5)
1 (<1)
1 (<1)
25 (13)

Population Receiving Bolus Infusions
(n = 166)

P
0.513
0.003
0.267
0.301
0.382
0.22

No Delayed
Elimination
(n = 50)

Delayed
Elimination
(n = 116)

P

34 (68)
49 (22)
2.03 (0.4)
101 (47)
15 (12)
38 (27)

63 (54)
57 (25)
1.98 (0.4)
77 (46)
21 (16)
46 (46)

0.101
0.005
0.012
<0.001
0.140
0.133

2 (4)
2 (4)
24 (48)
1 (2)
13 (26)
6 (12)
2 (4)
0.012
0.569

89 (77)
1 (1)
12 (10)
14 (12)

7000 (2063)

7000 (1775)

42 (84)
5 (10)
3 (6)
0 (0)
0 (0)
8 (16)

93 (80)
19 (16)
4 (3)
0 (0)
1 (1)
25 (22)

0.280

1
1
0.527

0.855

0.453

1
1
0.411

Abbreviations: ALL, acute lymphoblastic leukemia; ALT, alanine transaminase; AST, aspartate transaminase; CNS, central nervous system; IQR,
interquartile range; NHL, non-Hodgkin’s lymphoma.

levetiracetam is delayed when coadministered with probenecid, and with this commonality, it is possible that the 2
drugs compete for tubular secretion.8
Despite the potential for this drug-drug interaction, it
was not observed in the current study. The only significant
predictor of time to nontoxic methotrexate concentration
and delayed elimination at any time was baseline creatinine
clearance. Baseline characteristics between the groups were
similar, besides those receiving levetiracetam being slightly
older, with a higher baseline ALT, and more likely to be
female. None of these discrepancies between groups are
believed to have affected the results. These characteristics
would have put the levetiracetam group at a disadvantage,
leading to potentially higher incidences of delayed elimination in those receiving levetiracetam, which was not
observed. Another difference noted between groups was in
the median methotrexate concentration at 24 hours, which
was higher in those not receiving levetiracetam when the

entire population was analyzed. This discrepancy between
groups was likely a result of the increased number of
patients receiving prolonged infusions in the group without
levetiracetam, which are typically associated with higher
24-hour methotrexate concentrations.
Though the current study does not suggest the presence
of an interaction, without a formal pharmacokinetic study,
an interaction cannot be ruled out. It is possible that patients
at risk for delayed elimination at baseline are at even higher
risk when levetiracetam is present. In the adult case report
described above, the patient had a slight delay in elimination in cycle 1, prior to starting levetiracetam. A slight delay
in methotrexate elimination in those with other risk factors
may be further enhanced in the presence of levetiracetam,
which may not have been captured in the current study
design. Although there was no significant difference
between the groups, patients receiving levetiracetam did
have a slightly higher incidence of delayed elimination at
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any time (71% vs 76% in the entire population; 68% vs 76%
in the bolus infusion population) and a slightly longer time
to methotrexate concentration <0.1 µmol/L (72 vs 78 hours
in both the entire population and the bolus infusion population). These slight differences could be significant to a
patient with additional risk factors for delayed elimination.
Additionally, this study did not record the incidence of
adverse events; therefore, it is possible that patients receiving concomitant levetiracetam had a higher frequency of
adverse events despite insignificant changes in methotrexate elimination. However, this is unlikely because of the
strong correlation between methotrexate serum concentrations and the rate of adverse events.3 This study was limited
by the retrospective nature and limited number of patients
receiving levetiracetam concomitantly with methotrexate.

Conclusion
This study did not detect a difference in methotrexate elimination caused by coadministration of levetiracetam and
methotrexate and refutes the hypothesis generated by the 2
case reports; however, one of the cases included a dose of
12 g/m2, whereas the other included a dose of 5 g/m2. In this
study, the median dose was 3.5 g/m2. Delayed elimination
caused by concomitant levetiracetam administration cannot
be completely ruled out without a prospective, controlled,
formal pharmacokinetic analysis; however, a clinically significant interaction is unlikely in those without additional
risk factors for delayed elimination.
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